Open AccessNaproxen aggravates doxorubicin-induced cardiomyopathy in rats
Author(s) -
Rahila Ahmad Pathan,
Bhulan Kumar Singh,
K. K. Pillai,
Kiran Dubey
Publication year - 2010
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.62411
Subject(s) - doxorubicin , tbars , pharmacology , naproxen , oxidative stress , catalase , lactate dehydrogenase , superoxide dismutase , chemistry , nap , medicine , amifostine , cardiomyopathy , lipid peroxidation , enzyme , toxicity , biochemistry , heart failure , chemotherapy , pathology , alternative medicine , neuroscience , biology
The repercussion of the heated dispute on cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs) led to the national and international withdrawal of several of the recently introduced coxibs. Further debate and research have highlighted risks of the classical NSAIDs too. There is much controversy about the cardiovascular safety of a nonselective NSAID naproxen (NAP) and its possible cardioprotective effect.